Results 101 to 110 of about 71,226 (307)
ABSTRACT Background There is limited evidence on the safety and efficacy of biodegradable‐polymer sirolimus‐eluting ultra‐thin stent (BP‐SES) in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). Aims This study aims to evaluate the clinical outcomes of HBR patients treated with BP‐SES and ≤ 30‐day dual ...
Andrea Erriquez+9 more
wiley +1 more source
Emotions and scope effects in the monetary valuation of health [PDF]
JEL classifications: H41 H51 I11 I18 I31This study presents evidence on the role of emotions in the monetary evaluation of health technologies, namely, drug-eluting stents (DES) in our case.
Araña, Jorge+3 more
core +1 more source
Molecular atherectomy for restenosis [PDF]
Receptors for basic (b) and acidic (a) fibroblast growth factor (FGF) are upregulated in activated smooth muscle cells. These cells, which proliferate in response to bFGF, can thus be killed by a conjugate of bFGF and the ribosome-inactivating enzyme, saporin (which, by itself, does not enter the cells).
Douglas A. Lappi+2 more
openaire +3 more sources
ABSTRACT Background Fractional flow reserve (FFR) following percutaneous coronary intervention (PCI) can be used to evaluate procedural success and to guide stent optimization. Several studies have demonstrated that lower FFR after stent implantation is associated with increased adverse event rates up to 2 years.
Frederik T. W. Groenland+13 more
wiley +1 more source
Identification of Hemodynamically Optimal Coronary Stent Designs Based on Vessel Caliber [PDF]
Coronary stent design influences local patterns of wall shear stress (WSS) that are associated with neointimal growth, restenosis, and the endothelialization of stent struts.
Gundert, Timothy J+4 more
core +1 more source
The Hybrid Approach to Intervention of Chronic Total Occlusions [PDF]
The "hybrid" approach to chronic total occlusion (CTO) percutaneous coronary intervention (PCI) was developed to provide guidance on optimal crossing strategy selection.
Banerjee, S+6 more
core +1 more source
ABSTRACT Background Coronary calcification is a well‐known marker of atherosclerotic plaque burden and a determinant of stent under expansion with unfavorable long‐term outcomes. Aims This sub study of the randomized BIOVASC trial aimed to compare immediate complete revascularization (ICR) and staged complete revascularization (SCR) in patients with ...
William Camilleri+10 more
wiley +1 more source
Genetic Variants in PHACTR1 & LPL Mediate Restenosis Risk in Coronary Artery Patients
Cynthia Al Hageh,1,* Stephanie Chacar,2,* Thenmozhi Venkatachalam,2 Dominique Gauguier,3,4 Antoine Abchee,5 Elie Chammas,6 Hamdan Hamdan,2 Siobhan O’Sullivan,1 Pierre Zalloua,1,7,8 Moni Nader2,7 1Department of Molecular Biology and Genetics ...
Al Hageh C+9 more
doaj
Small poly-L-lysines improve cationic lipid-mediated gene transfer in vascular cells in vitro and in vivo [PDF]
The potential of two small poly-L-lysines ( sPLLs), low molecular weight sPLL ( LMW-L) containing 7 - 30 lysine residues and L18 with 18 lysine repeats, to enhance the efficiency of liposome-mediated gene transfer ( GT) with cationic lipid DOCSPER {[}1,3-
Adam Golda+36 more
core +1 more source
Delayed Restenosis after Gamma Brachytherapy for In‐Stent Restenosis
Intracoronary brachytherapy is a promising modality for inhibition of in‐stent restenosis. However, there is a concern of late progression after brachytherapy. This case report describes delayed restenosis after brachytherapy.
Yoshio Kobayashi+2 more
openaire +3 more sources